C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pret
Go back to C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pret| Cache Capital Corp. (NASDAQ: CCCC) | Delayed: 4.12 -0.03 (0.72%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.15 | 52 Week High | $0.30 | |||
| Open | $4.17 | 52 Week Low | $0.30 | |||
| Day High | $4.41 | P/E | N/A | |||
| Day Low | $4.10 | EPS | $0.00 | |||
| Volume | 2,995,756 | |||||
| Cache Capital Corp. (NASDAQ: CCCC) | Delayed: 4.12 -0.03 (0.72%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.15 | 52 Week High | $0.30 | |||
| Open | $4.17 | 52 Week Low | $0.30 | |||
| Day High | $4.41 | P/E | N/A | |||
| Day Low | $4.10 | EPS | $0.00 | |||
| Volume | 2,995,756 | |||||
